% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Caramanna:275351,
      author       = {I. Caramanna and J. C. Reijneveld and P. M. van de Ven and
                      M. van den Bent and A. Idbaih and W. Wick$^*$ and M. J. B.
                      Taphoorn and L. Dirven and A. Bottomley and M. Klein and E.
                      Q. o. L. Group},
      collaboration = {E. B. T. Group},
      title        = {{A}ssociation between objective neurocognitive functioning
                      and neurocognitive complaints in recurrent high-grade
                      glioma: {L}ongitudinal evidence of cognitive awareness from
                      {EORTC} brain tumour trials.},
      journal      = {European journal of cancer},
      volume       = {186},
      issn         = {0014-2964},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-00720},
      pages        = {38 - 51},
      year         = {2023},
      abstract     = {Patients' reduced awareness of neurocognitive functioning
                      (NCF) may negatively affect the reliability of
                      patient-reported outcomes (PROs) and clinical
                      decision-making. This study evaluated cognitive awareness,
                      defined as the association between NCF and neurocognitive
                      complaints, over the disease course of patients with
                      recurrent high-grade glioma (HGG).We assessed NCF using the
                      EORTC core clinical trial battery and neurocognitive
                      complaints using the Medical Outcome Study questionnaire.
                      Patients were categorised as impaired or intact, based on
                      their neurocognitive performance. Spearman's rank
                      correlations were calculated between NCF and neurocognitive
                      complaints at baseline and each 12 weeks, until 36. The
                      association between changes in NCF and neurocognitive
                      complaints scores between these follow-up assessments was
                      determined using Pearson's correlation.A total of 546
                      patients were included. Neurocognitively impaired patients
                      (n = 437) had more neurocognitive complaints (range: 10.51
                      [p < 0.001] to 13.34 [p = 0.001]) than intact patients (n =
                      109) at baseline, at 12 and 24 weeks. In intact patients,
                      NCF and neurocognitive complaints were correlated for only
                      one domain at baseline (0.202, p = 0.036), while in impaired
                      patients correlations were more frequently found in various
                      domains and time points (range: 0.164 [p = 0.001] to 0.334
                      [p = 0.011]). Over the disease course, NCF and
                      neurocognitive complaints were correlated for only one
                      domain at baseline (0.357, p = 0.014) in intact patients
                      while in impaired patients they were correlated for more
                      domains and time points (range: 0.222 [p < 0.001] to 0.366
                      [p < 0.001]).Neurocognitively impaired patients with
                      recurrent HGG are aware of their neurocognitive limitations
                      at study entry and during follow-up, which should be
                      considered in clinical decision-making and when interpreting
                      PRO results.},
      keywords     = {Cognitive awareness (Other) / Glioma (Other) /
                      Neurocognitive complaints (Other) / Neurocognitive
                      functioning (Other)},
      cin          = {B320 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B320-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37028200},
      doi          = {10.1016/j.ejca.2023.02.029},
      url          = {https://inrepo02.dkfz.de/record/275351},
}